These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 4809201)

  • 1. Effect of clofibrate on plasma glucose and serum immunoreactive insulin in patients with hyperlipoproteinemia.
    Fenderson RW; Sekowski I; Mohan C; Deutsch S; Benjamin F; Samuel P
    Am J Clin Nutr; 1974 Jan; 27(1):22-8. PubMed ID: 4809201
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of obesity on the relationship between insulin and triglyceride levels in endogenous hypertriglyceridemia.
    Bagdade JD; Bierman EL; Porte D
    Diabetes; 1971 Oct; 20(10):664-72. PubMed ID: 5110698
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of clofibrate on glucose tolerance and insulin secretion in patients with endogenous hypertriglyceridemia (author's transl)].
    Schwandt P; Weisweiler P; Neureuther G; Wilkening J
    MMW Munch Med Wochenschr; 1976 Mar; 118(12):351-4. PubMed ID: 177863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of hyperlipidemia in the HGH-deficient state.
    Merimee TJ; Hollander W; Fineberg SE
    Metabolism; 1972 Nov; 21(11):1053-61. PubMed ID: 4342932
    [No Abstract]   [Full Text] [Related]  

  • 5. Diurnal patterns of blood sugar, plasma insulin, free fatty acid and triglyceride levels in normal subjects and in patients with type IV hyperlipoproteinemia and the effect of meal frequency.
    Schlierf G; Raetzer H
    Nutr Metab; 1972; 14(2):113-26. PubMed ID: 5051903
    [No Abstract]   [Full Text] [Related]  

  • 6. Human plasma fatty acid composition: the features of hyperlipoproteinemia and the influence of -linolenate and clofibrate.
    Takayasu K; Tada T; Okada F; Yoshikawa I
    Jpn Circ J; 1971 Sep; 35(9):1059-69. PubMed ID: 5172104
    [No Abstract]   [Full Text] [Related]  

  • 7. The relationship between insulin secretion and triglyceride concentration in endogenous lipemia.
    Eaton BP; Nye WH
    J Lab Clin Med; 1973 May; 81(5):682-95. PubMed ID: 4349136
    [No Abstract]   [Full Text] [Related]  

  • 8. Type IV hyperlipoproteinemia. A critical appraisal.
    Schonfeld G; Kudzma DJ
    Arch Intern Med; 1973 Jul; 132(1):55-62. PubMed ID: 4716427
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of clofibrate treatment on arginine-induced insulin secretion in endogenous hypertriglyceridemia.
    Fedele D; Tiengo A; Muggeo M; Nosadini R; Crepaldi G
    Atherosclerosis; 1976; 25(2-3):191-8. PubMed ID: 1008908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clofibrate on arginine-stimulated glucagon and insulin secretion in man.
    Eaton RP; Schade DS
    Metabolism; 1974 May; 23(5):445-54. PubMed ID: 4825301
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.
    Lithell H; Boberg J; Hedstrand H; Hellsing K; Ljunghall S; Vessby B
    Eur J Clin Pharmacol; 1977 Aug; 12(1):51-7. PubMed ID: 332503
    [No Abstract]   [Full Text] [Related]  

  • 12. Glucagon secretion in primary endogenous hypertriglyceridemia before and after clofibrate treatment.
    Tiengo A; Muggeo M; Assan R; Fedele D; Crepaldi G
    Metabolism; 1975 Aug; 24(8):901-14. PubMed ID: 1143089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of short-term clofibrate administration on glucose tolerance and insulin secretion in patients with chemical diabetes or hypertriglyceridemia.
    Ferrari C; Frezzati S; Romussi M; Bertazzoni A; Testori GP; Antonini S; Paracchi A
    Metabolism; 1977 Feb; 26(2):129-39. PubMed ID: 834147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultracentrifugal demonstration of floating beta lipoproteins in type 3 hyperlipoproteinemia. Diagnostic value.
    Aubry F; Lapierre YL; Noël C; Davignon J
    Ann Intern Med; 1971 Aug; 75(2):231-7. PubMed ID: 5558651
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
    Feldman EB; Gluck FB; Carter AC
    J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diurnal patterns of plasma triglycerides and free fatty acids in normal subjects and in patients with endogenous (type IV) hyperlipoproteinemia.
    Schlierf G; Reinheimer W; Stossberg V
    Nutr Metab; 1971; 13(2):80-91. PubMed ID: 5123770
    [No Abstract]   [Full Text] [Related]  

  • 17. Study of serum insulin in atherosclerotic patients with endogenous hypertriglyceridemia (type 3 and IV hyperlipoproteinemia).
    Kuo PT; Feng LY
    Metabolism; 1970 May; 19(5):372-80. PubMed ID: 5442617
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
    Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone secretion in primary endogenous hypertriglyceridemia.
    Muggeo M; Fedele D; Tiengo A; Crepaldi G
    Horm Metab Res; 1973 May; 5(3):224-5. PubMed ID: 4714551
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunoreactive insulin, glucose tolerance, and carbohydrate inducibility in types II, 3, IV, and V hyperlipoproteinemia.
    Glueck CJ; Levy RI; Fredrickson DS
    Diabetes; 1969 Nov; 18(11):739-47. PubMed ID: 5348517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.